NCT06268626 Detection of Endometrial Cancer Through Risk Modelling
| NCT ID | NCT06268626 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of British Columbia |
| Condition | Endometrial Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2024-10-10 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2024-10-10 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study goal is to investigate a non-invasive approach to predict endometrial cancer (EC) risk, better understand disease progression and identify opportunities for intervention. This two-part case-cohort prospective study will recruit patients whose abnormal uterine bleeding is being evaluated via endometrial biopsy. Participants will complete an online health questionnaire, and a subset will be invited to self-collect vaginal samples for sequencing. Selected sequenced participants will be invited for longitudinal monitoring (questionnaires, wearable fitness tracker) and an additional vaginal self-collection to identify persistent genetic mutations or microbiome alterations 6-8 months later.
Eligibility Criteria
Inclusion Criteria: Study Part A: * 40 years and older * Experiencing unexplained abnormal uterine bleeding (i.e., not from IUD, etc.) * Have an intact uterus * Referred for an endometrial biopsy Study Part B/Longitudinal monitoring: * Those selected for sequencing (from Part A) and who retained their uterus. Exclusion Criteria: Study Part A: * Endometrial sampling, pelvic radiation, or vaginal infection (vaginosis, yeast) in the past 3 months * Started hormone therapy (HRT, birth control, IUD) in the past year (with the exception of tamoxifen) * Intercourse, vaginal product use, or douching in the past 48 hours Study Part B/Longitudinal monitoring: * Same as Study Part A * EC or EIN, or anyone who is recommended a hysterectomy
Contact & Investigator
Aline Talhouk, PhD
PRINCIPAL INVESTIGATOR
University of British Columbia
Frequently Asked Questions
Who can join the NCT06268626 clinical trial?
This trial is open to female participants only, aged 40 Years or older, studying Endometrial Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06268626 currently recruiting?
Yes, NCT06268626 is actively recruiting participants. Contact the research team at a.talhouk@ubc.ca for enrollment information.
Where is the NCT06268626 trial being conducted?
This trial is being conducted at Vancouver, Canada.
Who is sponsoring the NCT06268626 clinical trial?
NCT06268626 is sponsored by University of British Columbia. The principal investigator is Aline Talhouk, PhD at University of British Columbia. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.